JP2002518409A - サイクリックソマトスタチン類似体 - Google Patents

サイクリックソマトスタチン類似体

Info

Publication number: JP2002518409A
Authority: JP; Japan
Prior art keywords: trp; phe; lys; imidazole; cyclo
Prior art date: 1998-06-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000554767A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002518409A5 (es

Inventor

ゴードン，トーマス・ディー

Original Assignee

ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

1999-06-11

Publication date

2002-06-25

1999-06-11 Application filed by ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス filed Critical ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス

2002-06-25 Publication of JP2002518409A publication Critical patent/JP2002518409A/ja

2006-03-02 Publication of JP2002518409A5 publication Critical patent/JP2002518409A5/ja

Status Pending legal-status Critical Current

Links

NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract description 23
150000001875 compounds Chemical class 0.000 claims abstract description 103
238000000034 method Methods 0.000 claims abstract description 64
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 29
125000000217 alkyl group Chemical group 0.000 claims description 85
BGMJZDBEIHGNEJ-UHFFFAOYSA-N 5-(3-methoxyphenyl)-1h-imidazole Chemical compound COC1=CC=CC(C=2N=CNC=2)=C1 BGMJZDBEIHGNEJ-UHFFFAOYSA-N 0.000 claims description 77
PJQHXDBJGQGWHK-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)phenol Chemical compound OC1=CC=CC(C=2N=CNC=2)=C1 PJQHXDBJGQGWHK-UHFFFAOYSA-N 0.000 claims description 52
125000003118 aryl group Chemical group 0.000 claims description 46
-1 -NR9R9 Chemical group 0.000 claims description 37
125000003545 alkoxy group Chemical group 0.000 claims description 30
241000124008 Mammalia Species 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
125000001475 halogen functional group Chemical group 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 20
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 19
125000004104 aryloxy group Chemical group 0.000 claims description 15
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 12
206010012735 Diarrhoea Diseases 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
230000003248 secreting effect Effects 0.000 claims description 10
XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 claims description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
125000003107 substituted aryl group Chemical group 0.000 claims description 9
ULKZTFQDSPKNMV-UHFFFAOYSA-N 5-tert-butyl-1h-imidazole Chemical compound CC(C)(C)C1=CN=CN1 ULKZTFQDSPKNMV-UHFFFAOYSA-N 0.000 claims description 8
230000033115 angiogenesis Effects 0.000 claims description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
239000001301 oxygen Substances 0.000 claims description 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
WQROVAMZYXDXAB-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1h-imidazole Chemical compound C1=CC(OC)=CC=C1C1=CN=CN1 WQROVAMZYXDXAB-UHFFFAOYSA-N 0.000 claims description 7
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
102000004877 Insulin Human genes 0.000 claims description 6
108090001061 Insulin Proteins 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
230000027119 gastric acid secretion Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
229940125396 insulin Drugs 0.000 claims description 6
208000030507 AIDS Diseases 0.000 claims description 5
208000000668 Chronic Pancreatitis Diseases 0.000 claims description 5
208000008279 Dumping Syndrome Diseases 0.000 claims description 5
206010033645 Pancreatitis Diseases 0.000 claims description 5
206010033647 Pancreatitis acute Diseases 0.000 claims description 5
206010033649 Pancreatitis chronic Diseases 0.000 claims description 5
208000008469 Peptic Ulcer Diseases 0.000 claims description 5
208000032395 Post gastric surgery syndrome Diseases 0.000 claims description 5
208000017442 Retinal disease Diseases 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 5
208000009311 VIPoma Diseases 0.000 claims description 5
208000024248 Vascular System injury Diseases 0.000 claims description 5
208000012339 Vascular injury Diseases 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 5
201000003229 acute pancreatitis Diseases 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
238000002512 chemotherapy Methods 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
239000003629 gastrointestinal hormone Substances 0.000 claims description 5
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
208000027866 inflammatory disease Diseases 0.000 claims description 5
208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
201000011116 pancreatic cholera Diseases 0.000 claims description 5
206010052097 Dawn phenomenon Diseases 0.000 claims description 4
208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 4
208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
150000007649 L alpha amino acids Chemical class 0.000 claims description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
208000030304 gastrointestinal bleeding Diseases 0.000 claims description 4
230000000968 intestinal effect Effects 0.000 claims description 4
208000017169 kidney disease Diseases 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
208000011906 peptic ulcer disease Diseases 0.000 claims description 4
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims description 4
230000002062 proliferating effect Effects 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
241000590002 Helicobacter pylori Species 0.000 claims description 3
229940123051 Somatostatin receptor agonist Drugs 0.000 claims description 3
229940121856 Somatostatin receptor antagonist Drugs 0.000 claims description 3
229940037467 helicobacter pylori Drugs 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
208000006784 Cutaneous Fistula Diseases 0.000 claims 2
210000004204 blood vessel Anatomy 0.000 claims 2
230000001939 inductive effect Effects 0.000 claims 2
229960000553 somatostatin Drugs 0.000 abstract description 22
108020003175 receptors Proteins 0.000 abstract description 15
102000005962 receptors Human genes 0.000 abstract description 14
102000005157 Somatostatin Human genes 0.000 abstract description 12
108010056088 Somatostatin Proteins 0.000 abstract description 12
108050001286 Somatostatin Receptor Proteins 0.000 abstract description 5
102000011096 Somatostatin receptor Human genes 0.000 abstract description 4
125000004122 cyclic group Chemical group 0.000 abstract description 4
230000001270 agonistic effect Effects 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
239000000203 mixture Substances 0.000 description 80
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
239000000243 solution Substances 0.000 description 54
238000001819 mass spectrum Methods 0.000 description 45
235000019439 ethyl acetate Nutrition 0.000 description 43
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
229940024606 amino acid Drugs 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 27
150000001413 amino acids Chemical class 0.000 description 26
210000004027 cell Anatomy 0.000 description 23
238000010511 deprotection reaction Methods 0.000 description 23
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 22
238000001914 filtration Methods 0.000 description 22
239000000047 product Substances 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000002253 acid Chemical class 0.000 description 21
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
229920005989 resin Polymers 0.000 description 19
239000011347 resin Substances 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
239000007787 solid Substances 0.000 description 16
230000008878 coupling Effects 0.000 description 15
238000010168 coupling process Methods 0.000 description 15
238000005859 coupling reaction Methods 0.000 description 15
238000000746 purification Methods 0.000 description 15
239000002904 solvent Substances 0.000 description 15
SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 14
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 14
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 14
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 14
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
238000001514 detection method Methods 0.000 description 14
229920006395 saturated elastomer Polymers 0.000 description 14
MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
125000006239 protecting group Chemical group 0.000 description 12
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 11
125000003277 amino group Chemical group 0.000 description 11
238000010647 peptide synthesis reaction Methods 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
239000012634 fragment Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
238000003756 stirring Methods 0.000 description 10
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
239000003054 catalyst Substances 0.000 description 9
150000002148 esters Chemical class 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
238000005897 peptide coupling reaction Methods 0.000 description 9
239000008363 phosphate buffer Substances 0.000 description 9
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
108010051696 Growth Hormone Proteins 0.000 description 8
102100038803 Somatotropin Human genes 0.000 description 8
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
150000008064 anhydrides Chemical class 0.000 description 8
238000003818 flash chromatography Methods 0.000 description 8
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
239000000122 growth hormone Substances 0.000 description 8
150000004820 halides Chemical group 0.000 description 8
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
239000012043 crude product Substances 0.000 description 7
239000003480 eluent Substances 0.000 description 7
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000027455 binding Effects 0.000 description 6
LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 6
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 6
239000006260 foam Substances 0.000 description 6
238000010992 reflux Methods 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000008096 xylene Substances 0.000 description 6
208000003200 Adenoma Diseases 0.000 description 5
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000012867 bioactive agent Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000001506 calcium phosphate Substances 0.000 description 5
229910000389 calcium phosphate Inorganic materials 0.000 description 5
235000011010 calcium phosphates Nutrition 0.000 description 5
238000000975 co-precipitation Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 5
125000004494 ethyl ester group Chemical group 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000007363 ring formation reaction Methods 0.000 description 5
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
102000011923 Thyrotropin Human genes 0.000 description 4
108010061174 Thyrotropin Proteins 0.000 description 4
YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000029936 alkylation Effects 0.000 description 4
238000005804 alkylation reaction Methods 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000008188 pellet Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WWQYTEPUEUNBOM-SANMLTNESA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)ON1C(=O)CCC1=O WWQYTEPUEUNBOM-SANMLTNESA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
102000051325 Glucagon Human genes 0.000 description 3
108060003199 Glucagon Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
208000006809 Pancreatic Fistula Diseases 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108091036066 Three prime untranslated region Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
235000008206 alpha-amino acids Nutrition 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000000010 aprotic solvent Substances 0.000 description 3
150000001718 carbodiimides Chemical class 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
229960004666 glucagon Drugs 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
239000012026 peptide coupling reagents‎ Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000003880 polar aprotic solvent Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000002953 preparative HPLC Methods 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000010532 solid phase synthesis reaction Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000003512 tertiary amines Chemical class 0.000 description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
VLXHZQQUTCVLGU-DEOSSOPVSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoate Chemical compound C([C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)ON1C(CCC1=O)=O)C1=CC=CC=C1 VLXHZQQUTCVLGU-DEOSSOPVSA-N 0.000 description 2
WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
IOOHBIFQNQQUFI-UHFFFAOYSA-N 2-bromo-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CBr)=C1 IOOHBIFQNQQUFI-UHFFFAOYSA-N 0.000 description 2
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
206010000599 Acromegaly Diseases 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
108010001478 Bacitracin Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
101000632994 Homo sapiens Somatostatin Proteins 0.000 description 2
208000008081 Intestinal Fistula Diseases 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
229960003071 bacitracin Drugs 0.000 description 2
229930184125 bacitracin Natural products 0.000 description 2
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
238000000132 electrospray ionisation Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
KOUAQOCYMAENKN-UHFFFAOYSA-N ethyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
102000045305 human SST Human genes 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
125000004464 hydroxyphenyl group Chemical group 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
230000014399 negative regulation of angiogenesis Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920005990 polystyrene resin Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940108519 trasylol Drugs 0.000 description 2
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
KMMADXKPJGTBMH-VBQDKOLLSA-N (1S)-1-(5-tert-butyl-1H-imidazol-2-yl)-2-phenylethanamine (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound C(=O)(OC(C)(C)C)N[C@@H](CC1=CC=CC=C1)C(=O)O.N[C@@H](CC1=CC=CC=C1)C=1NC=C(N1)C(C)(C)C KMMADXKPJGTBMH-VBQDKOLLSA-N 0.000 description 1
GWAVARVTNAASNN-INIZCTEOSA-N (1s)-1-[5-(3-methoxyphenyl)-1h-imidazol-2-yl]-2-phenylethanamine Chemical compound COC1=CC=CC(C=2N=C(NC=2)[C@@H](N)CC=2C=CC=CC=2)=C1 GWAVARVTNAASNN-INIZCTEOSA-N 0.000 description 1
JPJMNCROLRPFHI-QFIPXVFZSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)ON1C(=O)CCC1=O JPJMNCROLRPFHI-QFIPXVFZSA-N 0.000 description 1
CPJXMXQYRHNIFU-HNNXBMFYSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OC(C)(C)C)ON1C(=O)CCC1=O CPJXMXQYRHNIFU-HNNXBMFYSA-N 0.000 description 1
SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
ULSAJQMHTGKPIY-UHFFFAOYSA-N 1-chloro-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CCl ULSAJQMHTGKPIY-UHFFFAOYSA-N 0.000 description 1
JYQULILJPZXQGR-UHFFFAOYSA-N 2-(2-bromoethyl)-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)C(C(O)=O)CCBr JYQULILJPZXQGR-UHFFFAOYSA-N 0.000 description 1
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
POIGXVYPRGOWQD-UHFFFAOYSA-N 2-imidazol-1-ylphenol Chemical compound OC1=CC=CC=C1N1C=NC=C1 POIGXVYPRGOWQD-UHFFFAOYSA-N 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
ZYUVGYBAPZYKSA-UHFFFAOYSA-N 5-(3-hydroxybutan-2-yl)-4-methylbenzene-1,3-diol Chemical compound CC(O)C(C)C1=CC(O)=CC(O)=C1C ZYUVGYBAPZYKSA-UHFFFAOYSA-N 0.000 description 1
XGMAAWHEXKYZAV-PMERELPUSA-N 9h-fluoren-1-ylmethyl n-[(1s)-1-[5-(3-methoxyphenyl)-1h-imidazol-2-yl]-2-phenylethyl]carbamate Chemical compound COC1=CC=CC(C=2NC(=NC=2)[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2C3=C(C4=CC=CC=C4C3)C=CC=2)=C1 XGMAAWHEXKYZAV-PMERELPUSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000007821 HATU Substances 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101100219325 Phaseolus vulgaris BA13 gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
101100186801 Rattus norvegicus Ndst1 gene Proteins 0.000 description 1
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010038934 Retinopathy proliferative Diseases 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
AVAQMSIWQGMEAV-UXMRNZNESA-N benzyl (2s)-3-amino-2-[5-(4-methoxyphenyl)-1h-imidazol-2-yl]-3-phenylpropanoate Chemical compound C1=CC(OC)=CC=C1C1=CN=C([C@H](C(N)C=2C=CC=CC=2)C(=O)OCC=2C=CC=CC=2)N1 AVAQMSIWQGMEAV-UXMRNZNESA-N 0.000 description 1
125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
OGZJIDQBUZQTMZ-FQEVSTJZSA-N ethyl 4-[2-[(1s)-1-amino-2-phenylethyl]-4-(4-hydroxyphenyl)imidazol-1-yl]butanoate Chemical compound C([C@H](N)C1=NC(=CN1CCCC(=O)OCC)C=1C=CC(O)=CC=1)C1=CC=CC=C1 OGZJIDQBUZQTMZ-FQEVSTJZSA-N 0.000 description 1
GOZHOKFSBAGMDN-QHCPKHFHSA-N ethyl 6-[2-[(1s)-1-amino-2-phenylethyl]-4-(3-methoxyphenyl)imidazol-1-yl]hexanoate Chemical compound C([C@H](N)C1=NC(=CN1CCCCCC(=O)OCC)C=1C=C(OC)C=CC=1)C1=CC=CC=C1 GOZHOKFSBAGMDN-QHCPKHFHSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005283 haloketone group Chemical group 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
LNOLJFCCYQZFBQ-UHFFFAOYSA-N n-[(4-nitrophenyl)-phenylmethylidene]hydroxylamine Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=NO)C1=CC=CC=C1 LNOLJFCCYQZFBQ-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000005416 organic matter Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013034 phenoxy resin Substances 0.000 description 1
229920006287 phenoxy resin Polymers 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
229960001153 serine Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
CAIDNIYJDBLXQU-FQEVSTJZSA-N tert-butyl 2-[2-[(1s)-1-amino-2-phenylethyl]-4-(4-methoxyphenyl)imidazol-1-yl]acetate Chemical compound C1=CC(OC)=CC=C1C1=CN(CC(=O)OC(C)(C)C)C([C@@H](N)CC=2C=CC=CC=2)=N1 CAIDNIYJDBLXQU-FQEVSTJZSA-N 0.000 description 1
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
HPHZMMLDDFXFFH-QFIPXVFZSA-N tert-butyl 4-[2-[(1s)-1-amino-2-phenylethyl]-4-(4-methoxyphenyl)imidazol-1-yl]butanoate Chemical compound C1=CC(OC)=CC=C1C1=CN(CCCC(=O)OC(C)(C)C)C([C@@H](N)CC=2C=CC=CC=2)=N1 HPHZMMLDDFXFFH-QFIPXVFZSA-N 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

JP2000554767A 1998-06-16 1999-06-11 サイクリックソマトスタチン類似体 Pending JP2002518409A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US8950398P	1998-06-16	1998-06-16
US9818198A	1998-06-16	1998-06-16
US09/098,181		1998-06-16
US60/089,503		1998-06-16
PCT/US1999/013304 WO1999065942A1 (en)	1998-06-16	1999-06-11	Cyclic somatostatin analogs

Publications (2)

Publication Number	Publication Date
JP2002518409A true JP2002518409A (ja)	2002-06-25
JP2002518409A5 JP2002518409A5 (es)	2006-03-02

Family

ID=26780645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000554767A Pending JP2002518409A (ja)	1998-06-16	1999-06-11	サイクリックソマトスタチン類似体

Country Status (12)

Country	Link
EP (1)	EP1086131A1 (es)
JP (1)	JP2002518409A (es)
CN (1)	CN1200000C (es)
AR (1)	AR021161A1 (es)
AU (1)	AU745493B2 (es)
CA (1)	CA2335184A1 (es)
HU (1)	HUP0102902A3 (es)
NO (1)	NO20006320L (es)
PL (1)	PL345037A1 (es)
RU (1)	RU2242481C2 (es)
TW (3)	TWI242441B (es)
WO (1)	WO1999065942A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009519967A (ja) *	2005-12-14	2009-05-21	ブリストル−マイヤーズスクイブカンパニー	第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1086086E (pt)	1998-06-12	2005-02-28	Sod Conseils Rech Applic	Derivados imidazolilo e sua utilizacao como ligandos de receptores da somatostatina
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
ES2282275T3 (es) *	2000-08-01	2007-10-16	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Derivados de imidazolilo.
US20040186151A1 (en) *	2003-02-12	2004-09-23	Mjalli Adnan M.M.	Substituted azole derivatives as therapeutic agents
WO2006063465A1 (en) *	2004-12-15	2006-06-22	Diamedica Inc.	Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
ES2365815T3 (es) *	2005-12-14	2011-10-11	Bristol-Myers Squibb Company	Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
PT2337846T (pt)	2008-09-26	2018-04-05	Ambrx Inc	Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
EP2168983A1 (fr) *	2008-09-30	2010-03-31	Ipsen Pharma	Nouveaux composés octapeptidiques et leur utilisation thérapeutique
JP5535931B2 (ja)	2008-10-27	2014-07-02	武田薬品工業株式会社	二環性化合物
RU2020143060A (ru)	2016-02-09	2021-02-20	СиДиАрДи ВЕНЧЕРЗ ИНК.	Антагонисты рецепторов соматостатина и способы их применения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5770687A (en) *	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
GB9513224D0 (en) *	1995-06-29	1995-09-06	Sandoz Ltd	Organic compounds
US6673927B2 (en) *	1996-02-16	2004-01-06	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Farnesyl transferase inhibitors

1999
- 1999-06-11 JP JP2000554767A patent/JP2002518409A/ja active Pending
- 1999-06-11 CN CNB998075027A patent/CN1200000C/zh not_active Expired - Fee Related
- 1999-06-11 WO PCT/US1999/013304 patent/WO1999065942A1/en not_active Ceased
- 1999-06-11 CA CA002335184A patent/CA2335184A1/en not_active Abandoned
- 1999-06-11 PL PL99345037A patent/PL345037A1/xx not_active Application Discontinuation
- 1999-06-11 HU HU0102902A patent/HUP0102902A3/hu unknown
- 1999-06-11 AU AU48223/99A patent/AU745493B2/en not_active Ceased
- 1999-06-11 EP EP99931793A patent/EP1086131A1/en not_active Withdrawn
- 1999-06-11 RU RU2001101530/04A patent/RU2242481C2/ru not_active IP Right Cessation
- 1999-06-15 TW TW091115003A patent/TWI242441B/zh active
- 1999-06-15 AR ARP990102857A patent/AR021161A1/es unknown
- 1999-06-15 TW TW088110016A patent/TW527361B/zh not_active IP Right Cessation
- 1999-06-15 TW TW093100348A patent/TWI242442B/zh active
2000
- 2000-12-12 NO NO20006320A patent/NO20006320L/no not_active Application Discontinuation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009519967A (ja) *	2005-12-14	2009-05-21	ブリストル−マイヤーズスクイブカンパニー	第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ

Also Published As

Publication number	Publication date
RU2242481C2 (ru)	2004-12-20
TWI242442B (en)	2005-11-01
AU4822399A (en)	2000-01-05
NO20006320D0 (no)	2000-12-12
TWI242441B (en)	2005-11-01
WO1999065942A1 (en)	1999-12-23
EP1086131A1 (en)	2001-03-28
AU745493B2 (en)	2002-03-21
WO1999065942A8 (en)	2000-02-17
CN1305496A (zh)	2001-07-25
TW527361B (en)	2003-04-11
HUP0102902A2 (hu)	2002-01-28
PL345037A1 (en)	2001-11-19
TW200410986A (en)	2004-07-01
CA2335184A1 (en)	1999-12-23
AR021161A1 (es)	2002-07-03
NO20006320L (no)	2001-02-12
HUP0102902A3 (en)	2002-02-28
CN1200000C (zh)	2005-05-04

Publication	Publication Date	Title
US5006651A (en)	1991-04-09	Phosphinic acid derivatives
AU666673B2 (en)	1996-02-22	Peptides having growth hormone releasing activity
US5480870A (en)	1996-01-02	Tumor growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
EP0355793B1 (en)	1996-07-10	Neuropeptide Y agonists and partial agonists
JPH07165791A (ja)	1995-06-27	酵素抵抗性免疫変調ペプチド
JPH09507217A (ja)	1997-07-22	成長ホルモン放出特性を持つ化合物
KR20010022924A (ko)	2001-03-26	페네틸아민 유도체
EP1069137A1 (en)	2001-01-17	Peptides having thrombospondin-like activity and their therapeutic use
EP0355794A2 (en)	1990-02-28	Neuropeptide Y antagonists
JP2002518409A (ja)	2002-06-25	サイクリックソマトスタチン類似体
KR100629013B1 (ko)	2006-09-26	Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
IL145484A (en)	2006-12-31	LHRH antagonists have improved solubility properties
JP2000510453A (ja)	2000-08-15	成長ホルモン遊離特性を有する化合物
JP2003501443A (ja)	2003-01-14	ニューロメジンｂおよびソマトスタチンレセプターアゴニスト
US6602849B1 (en)	2003-08-05	Cyclic somatostatin analogs
US5942493A (en)	1999-08-24	LH-RH antagonists having improved action
AU627781B2 (en)	1992-09-03	Peptides having t cell suppressor activity
KR100460165B1 (ko)	2005-06-01	효과가향상된신규한lh-rh길항제
CA1105923A (en)	1981-07-28	Pentapeptides and methods
JP2010150253A (ja)	2010-07-08	肝癌を治療するための薬剤
CZ20004654A3 (cs)	2001-06-13	Cyklická analoga somatostatinu
JPH05279390A (ja)	1993-10-26	エンドセリン拮抗性環状ペンタペプチド
JPH08253498A (ja)	1996-10-01	ボンベシン類似体
HK1016999B (en)	2002-11-08	Novel lh-rh antagonists having improved action

Legal Events

Date	Code	Title	Description
2006-01-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060111
2006-01-12	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060111
2008-10-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081015
2009-01-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090114
2009-01-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090122
2009-04-08	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090407

JP2002518409A - サイクリックソマトスタチン類似体 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (2)

Family

ID=26780645

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (10)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events